DLSTP1: A Potential Drug Target and Biomarker (G1744)

Target Name: DLSTP1

NCBI ID: G1744

DLSTP1

Other Name(s): Dihydrolipoamide S-succinyltransferase pseudogene 1 | DLSTP | dihydrolipoamide S-succinyltransferase pseudogene 1

DLSTP1: A Potential Drug Target and Biomarker

DLSTP1 (doublestranded RNA-binding protein 1) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker.DLSTP1 has been shown to play a role in various cellular processes, including cell growth, apoptosis, and inflammation. Its unique structure and function have made it an attractive target for drug development.

Structure and Function

DLSTP1 is a 21-kDa protein that consists of two distinct domains: an N-terminal transmembrane domain and a C-terminal T-loop domain. The N-terminal domain is responsible for the protein's cytoplasmic localization, while the C-terminal domain is involved in the protein's stability and interaction with other cellular components.

One of the most significant features of DLSTP1 is its ability to bind to doublestranded RNA (dsRNA). This interaction between the protein and RNA creates a stable complex that can withstand various conditions, including high temperatures and denaturation.

DLSTP1 has been shown to play a role in regulating cellular processes that are critical for human health, such as cell growth, apoptosis, and inflammation. For example, studies have shown that high levels of DLSTP1 can promote cell proliferation and the development of cancer. Additionally, the protein has been linked to the regulation of apoptosis, which is a natural process that helps the body eliminate damaged or dysfunctional cells.

Furthermore,DLSTP1 has been shown to play a role in the regulation of inflammation. Its presence has been observed in various cellular contexts, including the regulation of immune cell function and the response to infection.

Drug Target Potential

The potential drug target for DLSTP1 is its ability to interact with doublestranded RNA and its role in regulating various cellular processes. This has led to the development of small molecules that can inhibit the activity of DLSTP1 and its ability to bind to RNA.

One of the most promising small molecules is a fragment of the protein that can inhibit the activity of DLSTP1 in cell culture. The fragment has been shown to be effective in inhibiting the growth of cancer cells and has the potential to be a useful cancer therapeutic.

Another small molecule that has been shown to interact with DLSTP1 is a compound that can inhibit the activity of the protein in cell culture. The compound has been shown to be effective in inhibiting the growth of cancer cells and has the potential to be a useful cancer therapeutic.

Biomarker Potential

The potential use of DLSTP1 as a biomarker is based on its ability to regulate various cellular processes that are critical for human health. The protein has been shown to play a role in the regulation of cell growth, apoptosis, and inflammation, which are processes that are closely associated with various diseases, including cancer and cardiovascular disease.

The ability of DLSTP1 to interact with doublestranded RNA has also made it an attractive target for the development of diagnostic tests for various diseases. For example, the presence of DLSTP1 has been shown to be associated with the development of certain types of cancer, including breast and ovarian cancer. This suggests that DLSTP1 may be a useful biomarker for the diagnosis and treatment of these diseases.

Conclusion

DLSTP1 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. Its unique structure and function have made it an attractive target for drug development, and its potential as a biomarker for various diseases makes it an important area of research. Further studies are needed to fully understand the role of DLSTP1 in cellular processes and its potential as a drug target and biomarker.

Protein Name: Dihydrolipoamide S-succinyltransferase Pseudogene 1

The "DLSTP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DLSTP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets